Common Contracts
6 similar Shareholder Support Agreement contracts by OncoMed Pharmaceuticals Inc
EX-10.2 4 d665634dex102.htm EX-10.2 FORM OF SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • May 5th, 2020 • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [insert name of shareholder] (“Shareholder”).
FORM OF SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [insert name of shareholder] (“Shareholder”).
SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco High Income Fund (“Fund”).
SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco Income Fund (“Fund”).
SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Invesco Asset Management Limited of Perpetual Park, Perpetual Park Drive, Henley-on-Thames, Oxfordshire, RG9 1HH, United Kingdom, a private company limited by shares with company registration number 00 949417 and registered in England and Wales (“Shareholder”), acting as agent for and on behalf of Invesco UK Strategic Income Fund (“Fund”).
FORM OF SHAREHOLDER SUPPORT AGREEMENTShareholder Support Agreement • December 6th, 2018 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SUPPORT AGREEMENT (this “Agreement”), dated as of December 5, 2018, is made by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Novartis Pharma AG, a Swiss corporation (“Shareholder”).
